BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended September 30, 2019
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here BAFNA PHARMACEUTICALS LTD. - 532989 - Sub: Compliance Certificate For The Half Year Ended 30Th September 2019 Ref: Regulation 7(3) Of The SEBI (LODR) Regulations, 2015
Compliance Certificate certifying maintenance of physical and electronic transfer facility under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the half year ended 30th September, 2019 is hereby enclosed for your reference. BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer Bafna Pharmaceuticals Ltd - 532989 - General Announcement
We would like to inform you that the Board at its meeting held on today approved the following : 1. The un-audited financial results for the first quarter ending 30th June 2019. Please find attached the un-audited financial results for first quarter ending 30th June 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. The Board has approved reconstitution of Audit Committee. The reconstituted Audit Committee composition are as follows: Sl No Name of Director Designation 1 Mr. V. Rajamani Chairman 2 Mr. Babulal Kamlesh Kumar Member 3 Mr. Paras Bafna Member 3. Pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company approved Tuesday, 27th August, 2019 as the RECORD DATE for capital reduction. BAFNA PHARMACEUTICALS LTD. - 532989 - Corporate Action-Intimation of Capital Reduction
We wish to inform you that pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company at its meeting held on 10th August, 2019 approved Tuesday, 27th August, 2019 as the RECORD DATE for the purpose of determining the eligible equity shareholders whose equity shares shall stand reduced, pursuant to the Resolution Plan approved by the Hon'ble National Company Law Board Tribunal, Chennai Bench vide its Order dated 1st February, 2019 (''Approved Resolution Plan') In terms of the Approved Resolution Plan, the number of Equity Shares existing as on record date shall be reduced to 10%. Bafna Pharmaceuticals Ltd - 532989 - Financial Result For The First Quarter Ending 30Th June 2019
We would like to inform you that the Board at its meeting held on today approved the following : 1. The un-audited financial results for the first quarter ending 30th June 2019. Please find attached the un-audited financial results for first quarter ending 30th June 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. The Board has approved reconstitution of Audit Committee. The reconstituted Audit Committee composition are as follows: Sl No Name of Director Designation 1 Mr. V. Rajamani Chairman 2 Mr. Babulal Kamlesh Kumar Member 3 Mr. Paras Bafna Member 3. Pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company approved Tuesday, 27th August, 2019 as the RECORD DATE for capital reduction. Bafna Pharmaceuticals Ltd - 532989 - Outcome of Board Meeting
We would like to inform you that the Board at its meeting held on today approved the following : 1. The un-audited financial results for the first quarter ending 30th June 2019. Please find attached the un-audited financial results for first quarter ending 30th June 2019 along with the Limited Review Report obtained from the statutory auditor of the Company. 2. The Board has approved reconstitution of Audit Committee. The reconstituted Audit Committee composition are as follows: Sl No Name of Director Designation 1 Mr. V. Rajamani Chairman 2 Mr. Babulal Kamlesh Kumar Member 3 Mr. Paras Bafna Member 3. Pursuant to Regulation 42 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board of Directors of the Company approved Tuesday, 27th August, 2019 as the RECORD DATE for capital reduction. Bafna Pharmaceuticals Ltd - 532989 - Board Meeting Intimation for First Quarter Result (30Th June 2019) And Other Business Matter
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2019 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Saturday, 10th August 2019 at the registered office of the Company, to inter alia consider and adopt un-audited financial results for the first quarter ending 30th June 2019 and fixing of record date for reduction of capital as per resolution plan and authorising directors and company secretary to take necessary steps and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public. BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended June 30, 2019
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer